Short Interest Moves 62% Lower For BMRN

The most recent short interest data has been released by the NASDAQ for the 03/28/2013 settlement date, which shows a 7,437,778 share decrease in total short interest for BioMarin Pharmaceutical Inc. ( BMRN) BMRN , to 4,533,643, a decrease of 62.13% since 03/15/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days (at the average volume) it would take to close out all of the open short positions if every share traded represented a short position being closed. Average daily volume for BMRN at the 03/28/2013 settlement increased to 1,436,158, as compared to 1,367,731 at the 03/15/2013 report. That brought "days to cover" down to 3.16, a 63.93% decrease from the 8.75 days to cover calculated at the previous short interest data release. The below chart shows the historical "days to cover" for BMRN at previous short interest release dates:

Loading+chart++2012+TickerTech.com

A decreased "days to cover" value could indicate that short sellers are no longer expecting the same decline in stock price they once were, or it could also indicate a long bet elsewhere was closed where BMRN had been shorted as a hedge.

START SLIDESHOW:
The 10 Most Shorted Stocks of the Dow »

The chart below shows the one year performance of BMRN shares, versus its 200 day moving average. Looking at this chart, BMRN's low point in its 52 week range is $31.91 per share, with $63.92 as the 52 week high point — that compares with a last trade of $63.74.

BioMarin Pharmaceutical Inc. Chart

According to the ETF Finder at ETF Channel, BMRN makes up 4.39% of the Biotech ETF (BBH) which is up by about 2.5% on the day Wednesday.

In afternoon trading Wednesday, BMRN was up about 2.1% on the day.

null

If you liked this article you might like

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

5 Top Stocks With 100% Buy Ratings Right Now

5 Top Stocks With 100% Buy Ratings Right Now

Why I Stay Very Focused on My Individual Stocks

Why I Stay Very Focused on My Individual Stocks

7 Winners and Losers From Biggest Biotech Conference of 2017

7 Winners and Losers From Biggest Biotech Conference of 2017

Bluebird Bio Becoming Household Name With This Promising Cancer Treatment

Bluebird Bio Becoming Household Name With This Promising Cancer Treatment